Swedish Orphan Biovitrum extends Cyanokit® cooperation with Merck Serono
(Thomson Reuters ONE) -
Stockholm, Sweden - April 1, 2010 - Swedish Orphan Biovitrum (STO: BVT) has
expanded its agreement with Merck Serono, a division of Merck KGaA, Darmstadt,
Germany, for the distribution of Cyanokit(®) (hydroxocobalamin). Under the
agreement the distribution territories will include Ireland, UK and The
Netherlands in addition to the existing territories the Nordic and the Baltic
countries.
"We are very pleased with the expanded and continued partnership with Merck
Serono and the opportunity to make the Cyanokit(®) antidote available in
additional countries. The new agreement is yet an acknowledgement of our
industry position and partnership network in the niche specialist and orphan
drug area in Europe," said Martin Nicklasson, CEO of Swedish Orphan Biovitrum
Group.
About Cyanokit(®)
Cyanokit(®) is a pharmaceutical antidote indicated for the treatment of known or
suspected cyanide poisoning. Cyanide poisoning may result from exposure to smoke
from closed space fires, inhalation, ingestion, or dermal exposure.
Administered intravenously, Cyanokit(®) may be used on the scene of an emergency
situation or at the hospital, where quick response is critical. Cyanokit(®) is
kept in ambulances and emergency rooms at hospitals, and may be stock piled by
governments to be used in case of industrial accidents or a terrorist attack
involving cyanide.
The active ingredient in Cyanokit(®), hydroxocobalamin, is a form of vitamin
B12. Hydroxocobalamin works by binding directly to the cyanide ions, creating
cyanocobalamin, a variant of vitamin B12, which is excreted in the urine.
Advantages of this approach are that methemoglobin is not produced and the
oxygen-carrying capacity of the victim's blood is not lowered.
Further information about Cyanokit(®) can be found at:
http://www.ema.europa.eu/humandocs/PDFs/EPAR/cyanokit/H-806-PI-en.pdf
Healthcare professionals should refer to national labeling texts, and not the
information above.
About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.
Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipeline within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com
For more information please contact:
Swedish Orphan Biovitrum:
Kennet Rooth, EVP Marketing & Sales
Phone +46 8 412 98 43
Kennet.Rooth(at)swedishorphan.com
Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
Erik.Kinnman(at)biovitrum.com
Martin Nicklasson, CEO
Phone: +46 8 697 20 00
Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on April 1, 2010 at 8:30 a.m. CET.
[HUG#1400148]
Press release April 1, 2010: http://hugin.info/134557/R/1400148/355554.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.04.2010 - 02:32 Uhr
Sprache: Deutsch
News-ID 1012376
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Stockholm
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 63 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Swedish Orphan Biovitrum extends Cyanokit® cooperation with Merck Serono
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
